← Back to all trials
Active Not Recruiting
NCT05242471
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Conditions: Crohn's Disease
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 703
Sponsor: Janssen Research & Development, LLC
Location: University of Alabama Liver Center Birmingham Alabama
Summary
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
* Confirmed diagnosis of moderate to severe CD as assessed by Crohn'
Source: ClinicalTrials.gov (NCT05242471). StuddyBuddy aggregates publicly available trial information.
